Motilal Oswal's research report on Procter and Gamble Hygiene and Health Care
PGHH reported sales growth of 12.6% in 4QFY23 (June year-end), higher than our exception, driven by premiumization and productivity interventions. The company beat our EBITDA/PBT/PAT estimates, as adspends were significantly lower than our expectation at 6.3% of sales (after jumping to 12.1% of sales in 3QFY23). While we remain positive on the long-term growth potential of the sanitary napkin and healthcare business, the uncertain pace of recovery and challenging valuations of ~65xFY24E EPS/~53xFY25E EPS lead us to maintain our Neutral rating.
Outlook
Nevertheless, the uncertain pace of sales and earnings recovery and expensive valuations of ~65xFY24E EPS/~53xFY25E EPS lead us to maintain our Neutral rating. We value the stock at 55x Mar’25E EPS, arriving at a TP of INR16,940.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Procter & Gamble Hygiene & Health Care - 29 -08 - 2023 - khan
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
